SCHEMBL7763103

SCHEMBL7763103

COC(=O)c1ccc(NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)c2cccs2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP3 P08254 4/20 0.56
MMP1 P03956 1/20 0.56
MMP7 P09237 1/20 0.56
L3MBTL1 Q9Y468 3/20 0.44
ALDH1A1 P00352 2/20 0.42
GAA P10253 2/20 0.42
FCER2 P06734 1/20 0.40
CAPN1 P07384 1/20 0.39
HSPA5 P11021 1/20 0.39
HSPA2 P54652 1/20 0.39
ANPEP P15144 1/20 0.39
HPGD P15428 1/20 0.39
MMP2 P08253 2/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 1/20 0.38
CTSL P07711 1/20 0.38
CTSS P25774 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7612289 1.00 MMP3 (0.56) MMP3MMP1MMP7L3MBTL1ALDH1A1
SCHEMBL7609075 1.00 MMP3 (0.56) MMP3MMP1MMP7L3MBTL1ALDH1A1
SCHEMBL7604865 1.00 MMP3 (0.56) MMP3MMP1MMP7L3MBTL1ALDH1A1
SCHEMBL7403919 0.88 MMP1 (0.52) MMP3MMP1MMP7L3MBTL1ALDH1A1
SCHEMBL7403920 0.88 MMP1 (0.52) MMP3MMP1MMP7L3MBTL1ALDH1A1
SCHEMBL7762371 0.85 MMP3 (0.61) MMP3MMP1MMP7L3MBTL1ALDH1A1
SCHEMBL7764954 0.83 MMP3 (0.56) MMP3MMP1MMP7L3MBTL1ALDH1A1
SCHEMBL7605447 0.83 MMP3 (0.56) MMP3MMP1MMP7L3MBTL1ALDH1A1
SCHEMBL7605453 0.83 MMP3 (0.56) MMP3MMP1MMP7L3MBTL1ALDH1A1
SCHEMBL7402056 0.81 MMP3 (0.42) MMP3MMP1MMP7L3MBTL1CAPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1098662-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2001-05-16 EP claimed
WO-2000004892-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2000-02-03 WO claimed
EP-1098662-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2001-05-16 EP disclosed
WO-2000004892-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2000-02-03 WO disclosed